Search results
Emend is an antiemetic, a medicine that prevents nausea (feeling sick) and vomiting. Emend is used in patients aged from 6 months to prevent nausea and vomiting caused by chemotherapy (medicines used to treat cancer).
The company that markets Emend is experiencing delays in the manufacturing process related to a change of colourant used to produce the medicine. This has led to a shortage of Emend powder for oral suspension. The shortage is not related to a quality defect of the product or a safety issue. The shortage is expected to last until the end of July ...
The European Medicines Agency's news announcements, information on meetings and events, public consultations and related information.
2 wrz 2015 · today announced that the U.S. Food and Drug Administration (FDA) has. approved a supplemental New Drug Application (sNDA) for EMEND ®. (aprepitant) capsules, a substance P/neurokinin 1 (NK1) receptor. antagonist. With this expanded indication, EMEND capsules are now. approved for use in combination with other antiemetic agents in patients.
Latest news on the European Medicines Agency, also known as the EMA, a European Union agency responsible for the evaluation and supervision of pharmaceuticals.
1 dzień temu · European stocks climb on energy boost; headed for weekly losses. an hour ago. Moody's says UK budget poses new challenge for public finances, FT reports. 1:07 AM PDT. United Kingdom. UK house...
EMEND increased the AUC of midazolam, a sensitive CYP3A4 substrate, 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of 2 mg midazolam was co-administered on Days 1 and 5 of a regimen of EMEND 125 mg on Day 1 and 80 mg/day on Days 2 to 5.
